We found that the prevalence of HER2-low and HER2-ultralow was 54.5% and 10.6%, respectively, among a cohort of 2869 patients with breast cancer, suggesting that approximately half of all breast cancer patients may benefit from HER2-low targeted treatments. Here, ERBB2 is linked to breast cancer.